Meeting
2014 ASCO Annual Meeting
Glyco-optimized trastuzumab-GEX, a novel anti-HER2 monoclonal antibody with ADCC activity: A phase I clinical study in patients with HER2-positive tumors.
Authors
Hellmut Samonigg
Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Hellmut Samonigg , Sara De Dosso , Antonella Perotti , Guenther Gastl , Bruno Dietrich , Kelvin Eckert , Hans Baumeister , Marc Oliver Salzberg , Steffen Goletz , Walter Fiedler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Developmental Therapeutics: Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT01409343
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2515)
DOI
10.1200/jco.2014.32.15_suppl.2515
Abstract #
2515
Poster Bd #
29
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.
First Author: Richard D Baird
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.
First Author: Fei Ma
Poster
2021 ASCO Annual Meeting
Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
First Author: Cong Xue